Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review
Open Access
- 20 September 2017
- journal article
- review article
- Published by Springer Nature in Hereditary Cancer in Clinical Practice
- Vol. 15 (1) , 1-9
Abstract
Selective estrogen receptor modulators, such as tamoxifen, reduce breast cancer risk by up to 50% in women at increased risk for breast cancer. Despite tamoxifen’s well-established efficacy, many studies show that most women are not taking up tamoxifen. This systematic literature review aimed to identify the motivators and barriers to tamoxifen use ‘s amongst high-risk women. Using MEDLINE, PsycINFO, and Embase plus reviewing reference lists of relevant articles published between 1995 and 2016, 31 studies (published in 35 articles) were identified, which addressed high-risk women’s decisions about risk-reducing medication to prevent breast cancer and were peer-reviewed primary clinical studies. A range of factors were identified as motivators of, and barriers to, tamoxifen uptake including: perceived risk, breast-cancer-related anxiety, health professional recommendation, perceived drug effectiveness, concerns about side-effects, knowledge and access to information about side-effects, beliefs about the role of risk-reducing medication, provision of a biomarker, preference for other forms of breast cancer risk reduction, previous treatment experience, concerns about randomization in clinical trial protocols and finally altruism. Results indicate that the decision for high-risk women regarding tamoxifen use or non-use as a risk-reducing medication is not straightforward. Support of women making this decision is essential and needs to encompass the full range of factors, both informational and psychological.Keywords
Funding Information
- Cancer Council NSW (ID SRP 13-02)
This publication has 53 references indexed in Scilit:
- Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant dataThe Lancet, 2013
- Long‐term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillanceCancer, 2011
- Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutationsEuropean Journal of Human Genetics, 2011
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010
- Patient Decisions About Breast Cancer Chemoprevention: A Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2010
- Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trialBreast Cancer Research and Treatment, 2010
- Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aidBreast Cancer Research and Treatment, 2009
- Interest in breast cancer chemoprevention among older womenBreast Cancer Research and Treatment, 2007
- “Why take it if you don’t have anything?” breast cancer risk perceptions and prevention choices at a public hospitalJournal of General Internal Medicine, 2006
- Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary PreventionAnnals of Surgical Oncology, 2001